ClinicalTrials.gg
CompletedNCT00789854RUBYUpdated May 23, 2012Results posted

Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients

A Phase 3 interventional study of Quetiapine XR and Lithium carbonate in Major Depressive Disorder and Treatment Resistant Depression, sponsored by AstraZeneca. Completed at 106 sites in 13 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-05-23.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
688
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing quetiapine in Depressive Disorder, Major — 1 open to participants now, 2 under way, none of them phase 3. quetiapine · Depressive Disorder, Major.

Enrollment
4th of 31
688 · median 60
Started
2008
with 4 others
Phase 3
11 of 32
none open now
Registered
12th of 32
by date
Lead sponsor
8 of 32
AstraZeneca

Among the 32 studies testing quetiapine in Depressive Disorder, Major, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2008, is one of 11 in phase 3, and was the 12th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 32 studies testing quetiapine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About quetiapine

quetiapine: first FDA approval 1997 (SEROQUEL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing quetiapine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an selective serotonin reuptake inhibitor or Venlafaxine versus Quetiapine extended release monotherapy in subjects with treatment resistant depression as assessed by the changes from randomisation to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. As an independent objective, the primary objective will also be evaluated in two subgroups of patients: (1) patients who were resistant to two previous antidepressant therapies and (2) in the subgroup of patients with one previous failure.

Read the detailed description

The secondary objectives of the study are to compare the effects of the three different treatment regimen as assessed by the following variables and, if applicable, by their changes from randomisation to week 6 (end of study). Additionally the time of onset of therapeutic effect will be assessed by evaluating efficacy data after the first four days (Day 4) of treatment as well as after the first week of treatment (Day 8). These analyses will also be performed in the subgroups of patients with 2 failed previous antidepressants and patients with 1 failure.

03

Conditions studied

  • Major Depressive Disorder
  • Treatment Resistant Depression

Keywords

  • Depression
  • MDD
  • TRD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented clinical diagnosis as confirmed by the M.I.N.I. meeting criteria from the , 4th Edition (DSM-IV) for any of the following:296.2x MDD, Single Episode296.3x MDD, Recurrent Episode
  • Current episode of depression present, at least 42 days prior to enrolment but not more than 18 months
  • MADRS-Score ≥ 25 at enrolment and randomisation

Exclusion criteria

Exclusion Criteria:

  • Patients with a Axis I disorder other than MDD within 6 months of randomisation
  • Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status
  • Patients who, in the investigator's judgment pose a current serious suicidal or homicidal risk, or have made a suicide attempt within the past 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
688 participants (actual)

Study arms

  • Active comparator
    Add-on Quetiapine XR+SSRI/Venlafaxine

    Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od). From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline.

    Drug: Quetiapine XR · Drug: SSRI/Venlafaxine

  • Active comparator
    Add-on Lithium+SSRI/Venlafaxine

    Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od). From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline.

    Drug: Lithium carbonate · Drug: SSRI/Venlafaxine

  • Active comparator
    Monotherapy Quetiapine XR

    Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)

    Drug: Quetiapine XR

Interventions

  • 300 mg once daily (od)

    Also known as: Seroquel XR

  • 900 mg once daily (od)

    Also known as: Quilonum Retard

  • DrugSSRI/Venlafaxine

    Drug page: Venlafaxine

    SSRI - doses within label, Venlafaxine dose up to 225 mg/day

06

What researchers measure

Primary outcomes

  1. Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)

    Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.

    Time frame: 6 weeks treatment

  2. Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)

    Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.

    Time frame: 6 weeks of treatment

Secondary outcomes

  1. Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients

    Number of patients in remission, with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

    Time frame: 6 weeks of treatment

  2. Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure

    Number of patients in remission with one previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

    Time frame: 6 weeks of treatment

  3. Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure

    Number of patients in remission with two previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

    Time frame: 6 weeks of treatment

  4. Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8

    Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤8. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

    Time frame: 6 weeks of treatment

  5. Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12

    Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤12. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

    Time frame: 6 weeks of treatment

  6. Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients

    Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better

    Time frame: 6 week of treatments

  7. Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure

    Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better

    Time frame: 6 weeks of treatment

  8. Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure

    Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better

    Time frame: 6 weeks of treatment

  9. Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients

    Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where lower value shows a larger improvement.

    Time frame: 6 weeks of treatment

  10. Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure

    Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.

    Time frame: 6 weeks of treatment

  11. Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure

    Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.

    Time frame: 6 weeks of treatment

  12. Change in Clinical Global Impression Scale (CGI-S), All Patients

    Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale form 1-7, where a lower value shows a larger improvement.

    Time frame: 6 weeks of treatment

  13. Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure

    Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.

    Time frame: 6 weeks of treatment

  14. Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure

    Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.

    Time frame: 6 weeks of treatment

  15. Change in Beck Depression Inventory (BDI)

    Self-rating assessment of depressive symptoms using Beck Depression Inventory (BDI). Scale from 0-63, where a lower value shows a larger improvement.

    Time frame: 6 weeks of treatment

  16. Change in Pain, Measured by Visual Analog Scale (VAS)

    Self-rating assessment of pain using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.

    Time frame: 6 weeks of treatment

  17. Change in Anxiety Measured by Visual Analog Scale (VAS)

    Self-rating assessment of anxiety using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.

    Time frame: 6 weeks of treatment

  18. Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory

    Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)

    Time frame: 6 weeks of treatment

  19. Change in Anxiety Measured by STAI, Trait Anxiety Inventory

    Self-rating assessment of anxiety measured by State-Trait Anxiety Inventory (STAI), trait anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)

    Time frame: 6 weeks of treatment

  20. Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4

    Sleeping quality measured by Montgomery-Asberg Depression Rating Scale (MADRS) item 4 (reduced sleep) (Scale 0-6, where a lower value shows a larger improvement)

    Time frame: 6 weeks of treatment

  21. Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)

    Self-rated sleeping quality measured by PSQI (Scale 0-21, subscales 0-3, 18 questions, where a lower value shows a larger improvement)

    Time frame: 6 weeks of treatment

  22. Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component

    Self rating assessment of quality in life using SF-36, mental component (Scale 0-100, where a higher value shows a larger improvement)

    Time frame: 6 weeks of treatment

  23. Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component

    Self rating assessment of quality in life using SF-36, physical component (Scale 0-100, where a higher value shows a larger improvement)

    Time frame: 6 weeks of treatment

  24. Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility

    Self rating assessment of quality in life using EQ-5D utility (Scale 0-100, where a higher value shows a larger improvement)

    Time frame: 6 weeks of treatment

  25. Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)

    Self rating assessment of working productivity using WPAI:GH (Scale 0 to number of hours worked during a week multiplied with the salary in Euro, a lower value shows a larger improvement)

    Time frame: 6 weeks of treatment

  26. Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients

    The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm (225, 229 or 221).

    Time frame: 6 weeks of treatment

  27. Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure

    The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.

    Time frame: 6 weeks of treatment

  28. Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures

    The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.

    Time frame: 6 week of treatments

07

Results

Posted May 23, 2012

Participant flow

This was a 3 arm, open-label randomised, rater blinded, parallel group study comparing quetiapine XR monotherapy and augmentation with lithium augmentation in patients with treatment resistant depression, Recruitment period 6 November 2008 to 19 June 2009

Participant flow — Overall Study
MilestoneQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Started228231229
Completed179196182
Not completed493547
Withdrew: Adverse event282318
Withdrew: Lost to follow-up114
Withdrew: Withdrawal by subject9617
Withdrew: Eligibility criteria not fulfilled251
Withdrew: Severe non-compliance to the protocol300
Withdrew: Safety reasons002
Withdrew: Other605

Outcome measures

PrimaryChange in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)

Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.

Time frame:
6 weeks treatment
Reported as:
Least squares mean · scores on a scale
Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)-16.2 ± 0.843-17.2 ± 0.826-14.9 ± 0.97
Statistical analysis
  • Add-on Quetiapine XR vs Add-on Lithium · ANCOVA · Mean difference (final values): -2.322 · 97.5% CI -4.6 to -0.05Non-inferiority between add-on quetiapine XR and add-on lithium was shown in the Per Protocol analysis set.
  • Quetiapine XR Mono vs Add-on Lithium · ANCOVA · Mean difference (final values): -1.639 · 97.5% CI -3.24 to 1.312Non-inferiority between quetiapine XR mono and add-on lithium was shown in the Per Protocol analysis set.
PrimaryChange in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)

Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · scores on a scale
Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)-13.9 ± 0.806-15.1 ± 0.797-13.3 ± 0.801
Statistical analysis
  • Add-on Quetiapine XR vs Add-on Lithium · ANCOVA · p = 0.0489 (Adjustment for multiplicity was done, alpha = 0.025)Superiority testing of primary outcome showed no significant difference in the Modified Intention To Treat (ITT) population
  • Quetiapine XR Mono vs Add-on Lithium · ANCOVA · p = 0.4368 (Adjustment for multiplicity was done, alpha = 0.025)Superiority testing of primary outcome showed no significant difference in the Modified Intention To Treat (ITT) population
SecondaryDepression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients

Number of patients in remission, with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

Time frame:
6 weeks of treatment
Reported as:
Number · Participants
Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients537360
SecondaryDepression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure

Number of patients in remission with one previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

Time frame:
6 weeks of treatment
Reported as:
Number · Participants
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure224231
SecondaryDepression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure

Number of patients in remission with two previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

Time frame:
6 weeks of treatment
Reported as:
Number · Participants
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure313129
SecondaryDepression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8

Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤8. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

Time frame:
6 weeks of treatment
Reported as:
Number · Participants
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8355845
SecondaryDepression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12

Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score ≤12. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.

Time frame:
6 weeks of treatment
Reported as:
Number · Participants
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12678973
SecondaryResponse Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients

Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better

Time frame:
6 week of treatments
Reported as:
Number · Participants
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients114120102
SecondaryResponse Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure

Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better

Time frame:
6 weeks of treatment
Reported as:
Number · Participants
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure546553
SecondaryResponse Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure

Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction ≥ 50% compared to baseline, the higher number of patients the better

Time frame:
6 weeks of treatment
Reported as:
Number · Participants
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure605549
SecondaryResponder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients

Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where lower value shows a larger improvement.

Time frame:
6 weeks of treatment
Reported as:
Mean · scores on a scale
Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients-1.54 ± 1.24-1.85 ± 1.34-1.58 ± 1.32
SecondaryResponder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure

Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.

Time frame:
6 weeks of treatment
Reported as:
Mean · scores on a scale
Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure-1.42 ± 1.17-1.91 ± 1.31-1.62 ± 1.27
SecondaryResponder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure

Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.

Time frame:
6 weeks of treatment
Reported as:
Mean · scores on a scale
Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure-1.67 ± 1.30-1.79 ± 1.36-1.54 ± 1.38
SecondaryChange in Clinical Global Impression Scale (CGI-S), All Patients

Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale form 1-7, where a lower value shows a larger improvement.

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · scores on a scale
Change in Clinical Global Impression Scale (CGI-S), All Patients
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Clinical Global Impression Scale (CGI-S), All Patients-1.43 ± 0.101-1.65 ± 0.099-1.49 ± 0.1
SecondaryChange in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure

Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · scores on a scale
Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure-1.45 ± 0.133-1.82 ± 0.13-1.59 ± 0.13
SecondaryChange in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure

Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · scores on a scale
Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure-1.52 ± 0.133-1.55 ± 0.131-1.45 ± 0.135
SecondaryChange in Beck Depression Inventory (BDI)

Self-rating assessment of depressive symptoms using Beck Depression Inventory (BDI). Scale from 0-63, where a lower value shows a larger improvement.

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · scores on a scale
Change in Beck Depression Inventory (BDI)
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Beck Depression Inventory (BDI)-11.7 ± 0.926-13.5 ± 0.921-12.2 ± 0.922
SecondaryChange in Pain, Measured by Visual Analog Scale (VAS)

Self-rating assessment of pain using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · scores on a scale
Change in Pain, Measured by Visual Analog Scale (VAS)
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Pain, Measured by Visual Analog Scale (VAS)-9.47 ± 1.695-8.03 ± 1.681-8.3 ± 1.682
SecondaryChange in Anxiety Measured by Visual Analog Scale (VAS)

Self-rating assessment of anxiety using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · scores on a scale
Change in Anxiety Measured by Visual Analog Scale (VAS)
scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Anxiety Measured by Visual Analog Scale (VAS)-21.2 ± 1.972-23.4 ± 1.947-20.6 ± 1.952
SecondaryChange in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory

Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · Scores on a scale
Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory
Scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory-0.62 ± 0.3470.014 ± 0.344-0.87 ± 0.35
SecondaryChange in Anxiety Measured by STAI, Trait Anxiety Inventory

Self-rating assessment of anxiety measured by State-Trait Anxiety Inventory (STAI), trait anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · Scores on a scale
Change in Anxiety Measured by STAI, Trait Anxiety Inventory
Scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Anxiety Measured by STAI, Trait Anxiety Inventory-1.01 ± 0.331-1.36 ± 0.328-1.39 ± 0.331
SecondaryChange in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4

Sleeping quality measured by Montgomery-Asberg Depression Rating Scale (MADRS) item 4 (reduced sleep) (Scale 0-6, where a lower value shows a larger improvement)

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · MADRS item 4 score
Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4
MADRS item 4 scoreQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4-2.2 ± 0.108-2.4 ± 0.107-1.63 ± 0.108
SecondaryChange in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)

Self-rated sleeping quality measured by PSQI (Scale 0-21, subscales 0-3, 18 questions, where a lower value shows a larger improvement)

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · Scores on a scale
Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)
Scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)-4.77 ± 0.36-4.96 ± 0.358-3.51 ± 0.364
SecondaryChange in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component

Self rating assessment of quality in life using SF-36, mental component (Scale 0-100, where a higher value shows a larger improvement)

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · Scores on a scale
Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component
Scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component9.59 ± 0.92910.77 ± 0.9259.66 ± 0.932
SecondaryChange in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component

Self rating assessment of quality in life using SF-36, physical component (Scale 0-100, where a higher value shows a larger improvement)

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · Scores on a scale
Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component
Scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component5.224 ± 0.8115.065 ± 0.8134.566 ± 0.817
SecondaryChange in Quality of Life Measured by Health Questionnaire EQ-5D as Utility

Self rating assessment of quality in life using EQ-5D utility (Scale 0-100, where a higher value shows a larger improvement)

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · Scores on a scale
Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility
Scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility0.184 ± 0.0230.224 ± 0.0230.208 ± 0.023
SecondaryChange in Work Productivity and Activity Impairment: General Health (WPAI:GH)

Self rating assessment of working productivity using WPAI:GH (Scale 0 to number of hours worked during a week multiplied with the salary in Euro, a lower value shows a larger improvement)

Time frame:
6 weeks of treatment
Reported as:
Least squares mean · Scores on a scale
Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)
Scores on a scaleQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)-233 ± 0.023-185 ± 0.023-299 ± 0.023
SecondaryChange in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients

The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm (225, 229 or 221).

Time frame:
6 weeks of treatment
Reported as:
Number · Participants
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients135146131
SecondaryChange in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure

The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.

Time frame:
6 weeks of treatment
Reported as:
Number · Participants
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure677569
SecondaryChange in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures

The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.

Time frame:
6 week of treatments
Reported as:
Number · Participants
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures
ParticipantsQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures687162

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Quetiapine XR Mono—5/228 (2.2%)93/228 (40.8%)
Add-on Quetiapine XR—5/231 (2.2%)90/231 (39%)
Add-on Lithium—2/229 (0.9%)41/229 (17.9%)
Most frequent serious events
Most frequent serious events
EventQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
DepressionPsychiatric disorders0/2283/2311/229
Affective DisorderPsychiatric disorders1/2280/2310/229
Psychotic DisorderPsychiatric disorders1/2280/2310/229
RestlessnessPsychiatric disorders1/2280/2310/229
Suicidal IdeationPsychiatric disorders1/2280/2310/229
OverdoseInjury, poisoning and procedural complications1/2280/2310/229
CholelithiasisHepatobiliary disorders0/2280/2311/229
DiarrhoeaGastrointestinal disorders0/2281/2310/229
ManiaPsychiatric disorders0/2281/2310/229
Most frequent other events
Most frequent other events
EventQuetiapine XR MonoAdd-on Quetiapine XRAdd-on Lithium
SomnolenceNervous system disorders22/22820/2310/229
Dry mouthGastrointestinal disorders13/22822/2316/229
FatigueGeneral disorders21/22813/2317/229
SedationNervous system disorders15/22811/2310/229
TremorNervous system disorders0/2280/23115/229
DizzinessNervous system disorders11/22814/2310/229
HeadacheNervous system disorders11/22810/23113/229

Baseline characteristics

Age Continuous
Age Continuous(years)Quetiapine XR MonoAdd-on Quetiapine XRAdd-on LithiumTotal
Mean47 (20 to 65)47 (20 to 67)47 (19 to 67)47 (19 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)Quetiapine XR MonoAdd-on Quetiapine XRAdd-on LithiumTotal
Female152162152466
Male736769209
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)(Participants)Quetiapine XR MonoAdd-on Quetiapine XRAdd-on LithiumTotal
Diagnose code 296.2x Major Depressive Disorder (MD503641127
Diagnose code 296.3x MDD, Recurrent175193180548
Montgomery-Asberg Depression Rating Scale (MADRS) total score
Montgomery-Asberg Depression Rating Scale (MADRS) total score(Units on a scale)Quetiapine XR MonoAdd-on Quetiapine XRAdd-on LithiumTotal
Mean33.74 ± 5.633.15 ± 5.3432.91 ± 5.233.32 ± 5.4
Weight
Weight(kg)Quetiapine XR MonoAdd-on Quetiapine XRAdd-on LithiumTotal
Mean75.3 ± 17.275.2 ± 1776.4 ± 16.175.8 ± 16.65
08

Study locations

106 sites
  • Research Site
    Garran, Australian Capital Territory, Australia
  • Research Site
    Brisbane, Queensland, Australia
  • Research Site
    Everton Park, Queensland, Australia
  • Research Site
    Townsville, Queensland, Australia
  • Research Site
    Gilberton, South Australia, Australia
  • Research Site
    Clayton, Victoria, Australia
  • Research Site
    Frankston, Victoria, Australia
  • Research Site
    Heidelberg, Victoria, Australia
  • Research Site
    Malvern, Victoria, Australia
  • Research Site
    Prahran, Victoria, Australia
  • Research Site
    Richmond, Victoria, Australia
  • Research Site
    Graz, Austria
  • Research Site
    Klagenfurt, Austria
  • Research Site
    Salzburg, Austria
  • Research Site
    Wels, Austria
  • Research Site
    Wiener NEUSTADT, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Assebroek, Belgium
  • Research Site
    Diest, Belgium
  • Research Site
    Liege, Belgium
  • Research Site
    Tielt, Belgium
  • Research Site
    Cerova Koria Village, Veliko Tarnovo, Bulgaria
  • Research Site
    Kardjali, Bulgaria
  • Research Site
    Pazardjik, Bulgaria
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Ruse, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Esbjerg N, Denmark
  • Research Site
    Frederiksberg, Denmark
  • Research Site
    Odense, Denmark
  • Research Site
    Aachen, Germany
  • Research Site
    Achim, Germany
  • Research Site
    Augsburg, Germany
  • Research Site
    Bad Homburg, Germany
  • Research Site
    Bad Honnef, Germany
  • Research Site
    Bad Saarow, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Bielefeld, Germany
  • Research Site
    Bochum, Germany
  • Research Site
    Butzbach, Germany
  • Research Site
    Chemnitz, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Duren, Germany
  • Research Site
    Dusseldorf, Germany
  • Research Site
    Ellwangen, Germany
  • Research Site
    Erbach, Germany
  • Research Site
    Gelsenkirchen, Germany
  • Research Site
    Gutersloh, Germany
  • Research Site
    Halle, Germany
  • Research Site
    Hattingen, Germany
  • Research Site
    Herborn, Germany
  • Research Site
    Kassel, Germany
  • Research Site
    Kothen, Germany
  • Research Site
    Neu-isenburg, Germany
  • Research Site
    Neubrandenburg, Germany
  • Research Site
    Nurnberg, Germany
  • Research Site
    Oldenburg, Germany
  • Research Site
    Ostfildern, Germany
  • Research Site
    Schwerin, Germany
  • Research Site
    Stuttgart, Germany
  • Research Site
    Westerstede, Germany
  • Research Site
    Wurzburg, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Gyor, Hungary
  • Research Site
    Gyula, Hungary
  • Research Site
    Nyiregyhaza, Hungary
  • Research Site
    Bressanone, BZ, Italy
  • Research Site
    Brunico, BZ, Italy
  • Research Site
    Cagliari, CA, Italy
  • Research Site
    Pisa, PI, Italy
  • Research Site
    Roma, RM, Italy
  • Research Site
    Bolzano, Italy
  • Research Site
    Catania, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Braga, Portugal
  • Research Site
    Coimbra, Portugal
  • Research Site
    Lisboa, Portugal
  • Research Site
    Santarem, Portugal
  • Research Site
    Bucharest, Romania
  • Research Site
    Craiova, Romania
  • Research Site
    Galati, Romania
  • Research Site
    Sibiu, Romania
  • Research Site
    Bratislava, Slovakia
  • Research Site
    Krupina, Slovakia
  • Research Site
    Levice, Slovakia
  • Research Site
    Liptovsky Mikulas, Slovakia
  • Research Site
    Michalovce Stranany, Slovakia
  • Research Site
    Presov, Slovakia
  • Research Site
    Roznava, Slovakia
  • Research Site
    Zilina-bytcica, Slovakia
  • Research Site
    Zlate Moravce, Slovakia
  • Research Site
    Sama de Langreo, Asturias, Spain
  • Research Site
    Salamanca, Castilla Leon, Spain
  • Research Site
    Zamora, Castilla Leon, Spain
  • Research Site
    Barcelona, Cataluna, Spain
  • Research Site
    Vigo, Galicia, Spain
  • Research Site
    Addlestone, Surrey, United Kingdom
  • Research Site
    Winnick, Warrington, United Kingdom

Showing the first 100 of 106 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bauer M, Dell'osso L, Kasper S, Pitchot W, Dencker Vansvik E, Kohler J, Jorgensen L, Montgomery SA. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord. 2013 Oct;151(1):209-19. doi: 10.1016/j.jad.2013.05.079. Epub 2013 Jun 27. PubMed 23810357 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2008
First posted
Nov 13, 2008
Start
Nov 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
May 23, 2012
Last update
May 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00789854
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 13, 2008
Start date
Nov 2008
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
May 23, 2012
Last update
May 23, 2012

Study contacts

Michael Bauer, professor
principal investigator · Germany
Birgit Ekholm, PhD
study director · AstraZeneca MC Sweden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Quetiapine · Lithium Carbonate · Venlafaxine

Start the discussion